Skip to main content
Caplight Logo









Accession Therapeutics Limited

Accession Therapeutics Limited

Private
OxfordHealthcare & Life Scienceshttps://www.accessiontherapeutics.com/

Last Round

Grant

Mar 24, 2026

Est. Valuation

$100.93M

Total Funding Raised

$44.23M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Accession Therapeutics Limited is a biopharmaceutical company developing a novel class of tumour-targeted immunotherapies through its proprietary TROCEPT platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

oncolytic virotherapyviral immunotherapyoncolytic virussolid tumor therapycancer immunotherapydrug delivery platformadenovirus vectorclinical stage biotechtargeted drug deliveryintratumoral immunotherapycold tumorcheckpoint inhibitor deliverytumor microenvironmentT-cell engagerbiopharma partnering

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Accession Therapeutics Limited Comparables

Compare Accession Therapeutics Limited with similar companies based on industry and business-model similarity.

Accession Therapeutics Limited comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
KaliVir Immunotherapeutics
87%
TILT Biotherapeutics
87%
Theolytics
86%

Accession Therapeutics Limited Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMar 24, 2026
VC RoundMar 18, 2026
VC RoundDec 4, 2025
VC RoundApr 25, 2024
Series ANov 21, 2022
Seed
Sep 20, 2021

Key People

Founding team and executive leadership

Bent Jakobsen

Founder and CEO

Founding Team

Jez Gerry

Chief Operating Officer, Head of Preclinical Development

Executive Team

Accession Therapeutics Limited Investors

Notable investors and investment history

Accession Therapeutics Limited investors
InvestorRounds
Birk VentureSeed, Series A
Cancer Research UKSeries A
iGlobe PartnersVC Round, Series A
Primavera Venture PartnersSeed, VC Round, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 24, 2026

    Received $9M in grant funding from the European Commission.

  • Mar 18, 2026

    $7.6M round raised

Accession Therapeutics Limited Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Accession Therapeutics Limited Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Accession Therapeutics Limited's valuation, stock price, and market status.

Firmographic Details

HeadquartersOxford
Year Founded2021
Last FundingMar 24, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?